Literature DB >> 17428804

chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.

Filip A Paczkowski1, Iain A Sharpe, Sébastien Dutertre, Richard J Lewis.   

Abstract

Monoamine neurotransmitter transporters for norepinephrine (NE), dopamine and serotonin are important targets for antidepressants and analgesics. The conopeptide chi-MrIA is a noncompetitive and highly selective inhibitor of the NE transporter (NET) and is being developed as a novel intrathecal analgesic. We used site-directed mutagenesis to generate a suite of mutated transporters to identify two amino acids (Leu(469) and Glu(382)) that affected the affinity of chi-MrIA to inhibit [(3)H]NE uptake through human NET. Residues that increased the K(d) of a tricyclic antidepressant (nisoxetine) were also identified (Phe(207), Ser(225), His(296), Thr(381), and Asp(473)). Phe(207), Ser(225), His(296), and Thr(381) also affected the rate of NE transport without affecting NE K(m). In a new model of NET constructed from the bLeuT crystal structure, chi-MrIA-interacting residues were located at the mouth of the transporter near residues affecting the binding of small molecule inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428804     DOI: 10.1074/jbc.M610813200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.

Authors:  Juan Zhen; Solav Ali; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

2.  Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters.

Authors:  Dilip K Tosh; Aaron Janowsky; Amy J Eshleman; Eugene Warnick; Zhan-Guo Gao; Zhoumou Chen; Elizabeth Gizewski; John A Auchampach; Daniela Salvemini; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2017-03-20       Impact factor: 7.446

Review 3.  Monoamine transporter structure, function, dynamics, and drug discovery: a computational perspective.

Authors:  Sankar Manepalli; Christopher K Surratt; Jeffry D Madura; Tammy L Nolan
Journal:  AAPS J       Date:  2012-08-24       Impact factor: 4.009

Review 4.  Hormone-like conopeptides - new tools for pharmaceutical design.

Authors:  Ashlin Turner; Quentin Kaas; David J Craik
Journal:  RSC Med Chem       Date:  2020-09-24

5.  Comparative modeling of the human monoamine transporters: similarities in substrate binding.

Authors:  Heidi Koldsø; Anja B Christiansen; Steffen Sinning; Birgit Schiøtt
Journal:  ACS Chem Neurosci       Date:  2012-11-08       Impact factor: 4.418

6.  Novel structure--function information on biogenic amine transporters revealed by site-directed mutagenesis and alkylation.

Authors:  Maarten E A Reith
Journal:  Neurochem Res       Date:  2013-03-27       Impact factor: 3.996

7.  The role of cysteines and histidins of the norepinephrine transporter.

Authors:  Birger Wenge; Heinz Bönisch
Journal:  Neurochem Res       Date:  2013-03-23       Impact factor: 3.996

8.  Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations.

Authors:  Xiaoqin Huang; Howard H Gu; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2009-11-12       Impact factor: 2.991

Review 9.  Targeting voltage-gated calcium channels for neuropathic pain management.

Authors:  Danielle Perret; Z David Luo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 10.  Overview of Monoamine Transporters.

Authors:  Shaili Aggarwal; Ole V Mortensen
Journal:  Curr Protoc Pharmacol       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.